Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-12-18

FDA Approved: CANCIDAS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for CANCIDAS (caspofungin acetate) from Merck Sharp & Dohme LLC to update its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cancidas (caspofungin)

Snippet

SUPPL AP for CANCIDAS (CASPOFUNGIN ACETATE)